Telix and ITM combine to form radiopharmaceutical entity

Telix Pharmaceuticals and ITM-Isotope Technologies Munich (ITM) announced their merger, a move intended to bolster Telix's position as a vertically integrated radiopharmaceutical company. The combination is expected to enhance capabilities across development, isotope production, and global manufacturing.

This integration will provide Telix access to ITM's established isotope production technology and supply chain expertise. The objective is to secure the consistent availability of critical radioisotopes used in diagnostic and therapeutic applications within nuclear medicine.

The merger aligns with Telix's long-term growth strategy, aiming to expand its commercial reach and operational capacity in the radiopharmaceutical market. The companies anticipate that the combined entity will be better positioned to meet the growing demand for radiopharmaceutical products.

This development represents a significant consolidation within the radiopharmaceutical sector. The transaction is subject to customary closing conditions, including regulatory approvals.